Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

The Pursuit of Ravensthorpe

Medallion Metals
3:27pm
March 31, 2025
MM8 continues to progress the Ravensthorpe Gold Project (RGP) from concept to reality. The company has received multiple funding and offtake proposals from various counterparties, including project financing offers of up to A$50m, permitting efforts remain underway. Exclusive negotiations with ASX-listed IGO Ltd for the acquisition of the Forrestania processing infrastructure are advancing, with binding documentation well progressed. MM8 anticipates completion of negotiations within the 12-month exclusivity period. We reiterate our SPECULATIVE BUY rating, increasing our target price to A$0.41ps (from A$0.32ps).

Right Time, Right Place, Right Commodity

Meeka Metals
3:27pm
March 31, 2025
Development of the Murchison Gold Project (MGP) is tracking well to schedule with first gold due mid-2025. Expansions work on the process plant are progressing to schedule. Key infrastructure of the larger 750kW ball mill, cyclone cluster and structures have been installed. Open pit mining has commenced ahead of schedule with mining rates ramping up well, achieving ~20kBCM (Bank Cubic Meter) per pay, first ore is expected in April. We reiterate our SPECULATIVE BUY rating, increasing our target price to A$0.25ps (previously A$0.23ps) a function of increased spot gold prices.

Remaining hope fades as second Phase 3 fails

Opthea
3:27pm
March 31, 2025
After disappointing results in the Phase 3 COAST trial, showing lead drug candidate sozinibercept combined with standard of care (SOC) Eylea failed to show an improvement in mean change in best correct visual acuity (BCVA) at 52 weeks, the primary endpoint, the company opted to accelerate the readout of its other Phase 3 trial (ShORe), comparing sozinibercept with SOC Lucentis over the same timeframe and with the same primary endpoint. Like COAST, the ShORe trial failed to demonstrate any statistical difference in BCVA when comparing sozinibercept combination therapy with SOC. Management continues to access its obligations under a 2002 inked development funding agreement (DFA), where the company may be required to pay amounts that could material impact its solvency.

27 months to get back on track…a challenging goal

Healius
3:27pm
March 31, 2025
The investor day provided an update on the Lumus sale (closes 1 May-25; cA$300m special dividend (41.3c/sh fully franked)), a brief trading update (volumes +4%, revenue +6.2%), and importantly, the go forward strategy, which aims for operating leverage in the high single digit range by the end of FY27. Management’s ‘T27 plan’ aspires to grow revenue and lower the cost base via improved workforce planning and digital enablement across customer service, lab modernisation and emerging diagnostics. While management is confident the right ingredients are in place to succeed, with only 30% of flagged milestones completed to date, and an estimated A$110m+ in cost savings/efficiencies (>10% of the cost base) required to deliver on the goal, we view it as challenging. We adjust FY25-27 estimates with our target price falling to $1.32 from $1.35. Hold.

A great buy

The Reject Shop
3:27pm
March 27, 2025
TRS has entered into a scheme implementation agreement with Dollarama (DOL-TSX) to acquire all shares for $6.68 per share, which is a 112% premium to the previous closing price. This values TRS equity at A$259m. We think this is a strong offer which represents 95% upside to our previously published target price of $3.50. We move our price target to align with the TRS scheme offer price of $6.68 per share. Given the share price is now trading in line with the offer price, we retain a HOLD recommendation.

International Spotlight

Berkshire Hathaway-B
3:27pm
March 27, 2025
Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe (BNSF), Berkshire Hathaway Energy, Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing.

Strong heartbeat

EBR Systems
3:27pm
March 27, 2025
CY25 results were in line with expectations, with adequate funding for more than six quarters at the current burn. We see little risk to FDA approval for the company’s wireless cardiac pacing device (WiSE) on or before 13 Apr-25, with 2H25 launch. We view commercial and manufacturing readiness, along with a reimbursement path that is both streamlined and incentivised, as helping to smooth the transition from developmental stage into a commercially viable medical device business. We make nominal changes to CY25-26 forecasts, but raise our DCF-based valuation to A$2.86 (from A$1.76) on increased probability of FDA approval. Speculative Buy maintained.

Simplifying the business

Catalyst Metals
3:27pm
March 26, 2025
CYL has agreed to sell the non-core Henty Gold Mine to Kaiser Reef (ASX.KAU) for an upfront consideration of A$33m. The agreement lowers group unit costs and grants CYL the option to acquire 50% of the 250ktpa Maldon processing plant in Victoria. Drilling at Trident continues to validate the belt-scale growth proposition at Plutonic, mineralisation has been intersected 430m along strike and 600m below the existing resource indicating potential for material mine life extension. We upgrade our recommendation to ADD and our price target moves to A$5.69ps (previously A$4.56ps).

International Spotlight

Eli Lilly
3:27pm
March 26, 2025
Eli Lilly and Co is an American pharmaceutical company headquartered in Indianapolis. It engages in the discovery, development, manufacture and sale of pharmaceutical products. Its portfolio of medicine includes treatments in the areas of bone muscle joints, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn.

International Spotlight

Novo Nordisk A/S
3:27pm
March 26, 2025
Novo Nordisk is a Danish multinational pharmaceutical company providing innovative treatment for five chronic diseases. Its products treat type 1 and 2 diabetes, obesity, haemophilia and growth disorders. It is most known for its diabetes treatments. Ozempic is its main revenue stream, which is for the treatment of adults with insufficiently controlled type 2 diabetes.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more